Form 4: Capricor Director Kelliher Receives 15,500 Stock Options

Capricor Therapeutics director Mike Kelliher was granted 15,500 stock options with an exercise price of $24.81, vesting monthly over 2026.

Summary

• Mike Kelliher, a Director of Capricor Therapeutics, Inc. (CAPR), was granted 15,500 stock options.
• The transaction date for this grant was January 5, 2026.
• The exercise price for these stock options is $24.81 per share.
• The options will vest at a rate of 1/12th on the first day of each month, commencing February 1, 2026, with the final vesting on December 31, 2026.
• The expiration date for these options is January 5, 2036.
• The award is for annual board service.
• The options are subject to early exercise, meaning they can be exercised at any time, but shares purchased prior to vesting will be restricted and subject to a repurchase option by the Issuer if service terminates early.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice for executive and board compensation, aiming to align interests with shareholders. It is a neutral to slightly positive event as it reflects ongoing board service and compensation structure.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The award reflects continued board service by Mike Kelliher, indicating stability in corporate governance.

Risks

• If the reporting person elects to exercise options early and their service to the Issuer terminates prior to vesting, the shares will be deemed restricted stock and subject to a repurchase option in favor of the Issuer.

Future Outlook

The vesting schedule extending through December 2026 indicates an expectation of continued board service by Mike Kelliher for at least the duration of the vesting period.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Equity compensation for board members, such as stock option grants, is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, typically over several years, is also common, designed to retain directors and incentivize sustained performance.
• The inclusion of an early exercise feature with a repurchase option is a standard mechanism to manage unvested equity upon termination of service, protecting the company's interests.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Mike Kelliher constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to better long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The stock options will begin vesting on February 1, 2026, and continue monthly until fully vested on December 31, 2026.
• Mike Kelliher may choose to exercise the options at any time, subject to the vesting schedule and repurchase provisions for early exercise.

Key Dates

Recommendation

This Form 4 details a routine equity grant to a director for annual board service. It does not present new material information that would significantly alter the company's valuation or investment outlook, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Capricor Therapeutics, CAPR, Stock Option, Director Compensation, Equity Grant, Insider Transaction, Form 4, Mike Kelliher